DOCSLIB.ORG

AAAAI 2016 Abstracts Monday

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
AAAAI 2016 Abstracts Monday All abstracts are strictly embargoed until the date of presentation at the 2016 Annual Meeting. AB202 Abstracts J ALLERGY CLIN IMMUNOL FEBRUARY 2016 Relationship Between Exhaled Breath Temperature The Asthma Control Test (ACT): Does It Reliably 655 and Ear Temperature in Otherwise Healthy Persons 657 Assess Asthma Control in African American during Febrile Infectious Illness Adolescents with Persistent Asthma? 1 2 3 1 1 Allison J. Burbank, MD , Katherine Mills, BA , Haibo Zhou, PhD , Todor A. Popov, MD, PhD , Tanya Kralimarkova , Lawrence M. 3 4 1 2,3 1 Qingning Zhou , Michelle L. Hernandez, MD ; UNC School of DuBuske, MD, FAAAAI ; Sofia Medical University, Sofia, Bulgaria, 2 2 Medicine, Chapel Hill, NC, University of North Carolina Chapel Hill George Washington University School of Medicine, Washington, DC, 3 3 School of Medicine, Chapel Hill, NC, University of North Carolina at Immunology Research Institute of New England, Gardner, MA. Chapel Hill, School of Public Health, 4University of North Carolina at RATIONALE: Exhaled breath temperature (EBT) is proposed as a Chapel Hill School of Medicine, Chapel Hill, NC. non-invasive marker of inflammation in obstructive airway diseases. RATIONALE: Measurement properties of the Asthma Control Test EBTand core body temperature (CBT) are not identical in normal persons. (ACT) are lacking in adolescent asthmatics, particularly among African This study assesses associations between EBT and CBT during febrile Americans who may under-report asthma symptoms and experience more illnesses. asthma-related morbidity and mortality. METHODS: Six generally healthy subjects, including 5 men, aged 42–64 METHODS: We propose that the accepted ACT scores used to determine years, had daily EBTassessed for 5 months and 2 years. All used hand-held Ò asthma control would have poor agreement with physician assessment of devices specifically engineered for personal use, the X-halo , DMI control in African American adolescents. We conducted an ongoing Singapore. They measured ear temperature (ET) to assess CBT. The prospective study of African American children ages 12-18 with persistent EBT devices had data uploaded automatically on an Internet site. The asthma. After completing the ACT and spirometry, the physician (blinded subjects were instructed to record ET at 8-hour intervals if the o to ACT score) performed a standardized assessment of asthma control. measurement exceeded 37 C. Frequency of EBT measurements were Agreement of an ACT score > 19 with physician assessment of control was increased during febrile illnesses. used to measure sensitivity, specificity, and Cohen k. RESULTS: Six episodes of fever were documented during the study: 2 RESULTS: Data for 22 subjects who completed at least one visit were cases of rhinovirus infections in which EBT rose by 1.2-1.9oC above base- o included in the analysis. Using a cut point of > 19 for asthma control, the line, preceding by 24-72 hours a moderate increase of ET (up to 38 C); 2 5 o ACT and physician’s assessment were somewhat in agreement (k 0.374, cases of influenza in which EBT rose by >2.0 C about 6 hours before ET 5 o p .08). In addition, a cut point of > 19 had a sensitivity of 77.8% and (up to 40 C); and 2 cases of bacterial infections, urinary and GI, in which specificity of 61.5% in this population. z o o EBT rose by 1.0 C simultaneously with ET (up to 39 C). CONCLUSIONS: Our results show only a fair level of agreement between CONCLUSIONS: EBT rises during incipient viral infections earlier than ACT score and physician assessment of asthma control in African American CBTas seen by ET, providing a window of opportunity for early treatment. adolescents with persistent asthma. While not statistically significant, our EBT assessment allows early detection of illness in patients at risk of data suggest that our effect size could be significant, but a larger sample size exacerbation of underlying obstructive airway diseases. is needed in order to reach significance. The cut off score of 19 was less Pulmonary Embolism in a Patient with Factor V specific for determining asthma control in African American teens compared 656 Leiden Mutation, Presenting with Symptoms of to previous studies of ACT accuracy in Caucasian adults. Asthma Exacerbation Characterization of Urge to Cough in Patients with 658 the Common Cold: Results from a US Internet Survey 1,2 3 1 Anil Nanda, MD , Anita N. Wasan, MD ; Asthma and Allergy Center, 1 2 2 3 Peter Dicpinigaitis, MD , Howard M. Druce, MD, FAAAAI , Ron Lewisville, TX, UT-Southwestern Medical Center, Dallas, TX, Allergy Eccles, BSc, PhD, DSc3, Ronald Turner, MD4, Maryann Attah, MPH5, and Asthma Center, Lansdowne, VA. Ashley L. Mann, MS5; 1Albert Einstein College of Medicine, 2Rutgers- RATIONALE: The differential diagnosis of asthma is extensive. NJ Medical School, 3Cardiff University Cardiff, 4University of Virginia, Pulmonary embolism may present with similar symptoms to asthma. We Charlottesville, VA, 5Pfizer Consumer Healthcare. present a case of pulmonary embolism in a patient with moderate persistent RATIONALE: Cough is typically thought to be a reflex, requiring primary asthma and Factor V Leiden mutation who presented with symptoms of an afferent input to the brainstem, leading to reflex changes in respiration. Urge asthma exacerbation. to cough represents an additional dimension, involving complex sensory and METHODS: Our patient was referred for evaluation and treatment of cognitive processes in higher brain centers. Individual experiences, moderate persistent asthma. perspectives, and management options for urge to cough were investigated. RESULTS: A 52 year old woman with a Factor V Leiden mutation METHODS: An Internet survey exploring cough attributes in respondents presented with a history of moderate persistent asthma. Symptoms who had contracted the common cold within the last 3 months was fielded in included cough, wheezing, and shortness of breath. She had been April 2015. Those with chronic cough were excluded. Demographics, urge previously treated with montelukast with no significant benefit. She could to cough attributes and impact, and management choices were elicited. not tolerate medications with long-acting beta agonists due to anxiety side RESULTS: Of 19,530 screened, 2,708 met inclusion/exclusion criteria; 58% effects. She was placed on fluticasone proprionate 220 mcg two puffs twice female; 85% white; 19% smoked tobacco; 8% used e-cigarettes. Urge to cough daily with benefit. However, after two months, she developed worsening was experienced by 97.8% of respondents and was uncontrollable in 64%. shortness of breath symptoms with wheezing. On exam, she had normal MONDAY Uncontrollability of urge to cough (62%), throat clearing (40.4%), and sore heart rate (80), respiratory rate (12), and blood pressure (110/70). Lung throat (35.6%) were the most bothersome aspects. Common triggers included exam was clear to auscultation without any wheezes, rhonchi, or rales. talking, cold air, or changing position. Attempts to prevent/treat urge to cough Fluticasone dose was increased with some benefit in two days, however, occurred in 74.3%; over-the-counter (OTC) drugs/syrups or lozenges were at mild symptoms still occurred. She then developed chest discomfort, which least somewhat effective in 83% and 78%, respectively. Prescriptions were used was exacerbated by arm movement. She was referred to emergency by 12.9%, and 89% felt they were ‘‘somewhat’’or ‘‘very’’effective. Healthcare department for further evaluation, and CT pulmonary angiography provider (HCP) advice was elicited by 16% and received by 86%. Advice revealed a pulmonary embolism. She was successfully treated with included prescription medications (66.5%), OTC medications (45.7%), herbal anticoagulant therapy. remedies (15.1%), and home remedies (12.6%); 96% followed HCP advice. CONCLUSIONS: This case demonstrates the importance of considering CONCLUSIONS: Urge to cough frequently accompanies the common pulmonary embolism in the differential diagnosis of an asthma cold. This Internet survey provided characterization of urge to cough exacerbation, especially in a patient with a hypercoagulable state, such attributes. Enhanced understanding of cough perception may lead to as Factor V Leiden. insights relevant to novel therapy. All abstracts are strictly embargoed until the date of presentation at the 2016 Annual Meeting. J ALLERGY CLIN IMMUNOL Abstracts AB203 VOLUME 137, NUMBER 2 Sterility Practices in Bronchodilator Administration Total Serum IgE Levels in Asthmatic Children 659 in Allergy Office Settings 661 1 2 Kabir S. Chhabra1, Johanna Wickemeyer1,2, Sudhir Sekhsaria, MD1, Cristine S. Rosario, MD , Nelson A. Rosario, MD, PhD,FAAAAI ,Her- 3 4 Naba A. Sharif, MD1; 1Asthma, Allergy & Sinus Center, Waldorf, MD, berto J. Chong Neto, MD, PhD, FAAAAI , Carlos Antonio Riedi, MD, PhD , 3 1 2Georgetown University School of Medicine, Washington, DC. Monica Lima ; Hospital de Clınicas, Federal University of Parana - Brazil, 2 3 RATIONALE: Due to the need for asthma diagnosis and surveillance, the curitiba, Brazil, Federal University of Parana, Curitiba, Brazil, Federal Uni- 4 bronchodilator reversibility test is commonly used. Yet, there are no versity of Parana, Brazil, Federal University of Parana, Curitiba, Brazil. complete, standardized guidelines for bronchodilator administration. RATIONALE: Total serum IgE levels (sIgE) are elevated in allergic Various methods are used to clean the Metered Dose Inhalers (MDIs), diseases and correlate with asthma severity in children.
Load more

Recommended publications
  • The Pathophysiology of Paroxysmal Nocturnal Haemoglobinuria.Pdf
    The Pathophysiology of Paroxysmal Nocturnal Haemoglobinuria Richard John Kelly Submitted in accordance with the requirements for the degree of Doctor of Philosophy The University of Leeds School of Medicine January 2014 1 Jointly-Authored Publications The candidate confirms that the work submitted is his own, except where work which has formed part of jointly authored publications has been included. The contribution of the candidate and the other authors to this work has been explicitly indicated below. The candidate confirms that appropriate credit has been given within the thesis where reference has been made to the work of others. The work in Chapter 3 of the thesis has appeared in publication as follows: Kelly RJ, Hill A, Arnold LM, Brooksbank GL, Richards SJ, Cullen M, Mitchell LD, Cohen DR, Gregory WM, Hillmen P. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood 2011;117:6786-6792. I was responsible for designing the study, collecting and analysing the data and writing the paper. Dena Cohen and Walter Gregory performed the statistical analysis. All the other authors reviewed the paper. The work in Chapter 4 of the thesis has appeared in publication as follows: Kelly R, Arnold L, Richards S, Hill A, Bomken C, Hanley J, Loughney A, Beauchamp J, Khursigara G, Rother RP, Chalmers E, Fyfe A, Fitzsimons E, Nakamura R, Gaya A, Risitano AM, Schubert J, Norfolk D, Simpson N, Hillmen P. The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab. Br J Haematol 2010;149:446-450. I was responsible for designing the study, collecting and analysing the data and writing the paper.
    [Show full text]
  • Substances That Target Tumor Metabolism
    Biomedical Research 2011; 22 (2): 132-166 1181_On the metabolic origin of cancer: substances that target tumor metabolism. Maurice Israël 1 and Laurent Schwartz 2 1Biorebus 38 rue de Bassano 75008 Paris ; and 2 Av Aristide Briand 91440 Bures sur Yvette. France. 2LIX : Ecole Polytechnique Palaiseau France ; and Hôpital Pitié- Salpêtrière, service de radiothérapie, 75013 Paris. Abstract. Work from our group and others clearly suggest the key role of altered metabolism in cancer. The goal of this review is to summarize current knowledge on cancer metabolism, draw hy- pothesis explaining metabolic alterations and associated gene changes. Most importantly, we indicate a list of possible pharmacological targets. In short, tumor metabolism displays mixed glycolysis and neoglucogenesis features; most glycolitic enzymes are activate, but the pyruvate kinase and the pyruvate deshydrogenase are inhibited. This would result from an activation of their specific kinases, or from the inactivation of phosphatases, such as PP2A, regulated by me- thylation. In parallel, the phosphatase failure would enhance “tyrosine kinase receptor” signals, as occurs with oncogenes. Such signaling pathways are similar to those activated by insuline, or IGF- Growth hormone; they control mitosis, cell survival, carbohydrate metabolism. If for some reason, their regulation fails (oncogenes, PP2A methylation deficit, enhanced kinases…) a typical tumor metabolism starts the carcinogenic process. We also describe changes in the citric acid- urea cycles, polyamines, and show how body stores feed tumor metabolic pathways above and below “bottlenecks” resulting from wrongly switched enzymes. Studying the available lit- erature, we list a number of medications that target enzymes that are essential for tumor cells.
    [Show full text]
  • Ilamycin C Induces Apoptosis and Inhibits Migration and Invasion In
    Xie et al. Journal of Hematology & Oncology (2019) 12:60 https://doi.org/10.1186/s13045-019-0744-3 RESEARCH Open Access Ilamycin C induces apoptosis and inhibits migration and invasion in triple-negative breast cancer by suppressing IL-6/STAT3 pathway Qing Xie1†, Zhijie Yang2†, Xuanmei Huang1, Zikang Zhang1, Jiangbin Li1, Jianhua Ju2*, Hua Zhang1* and Junying Ma2* Abstract Background: Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer with poor prognosis, and its treatment remains a challenge due to few targeted medicines and high risk of relapse, metastasis, and drug resistance. Thus, more effective drugs and new regimens for the therapy of TNBC are urgently needed. Ilamycins are a kind of cyclic peptides and produced by Streptomyces atratus and Streptomyces islandicus with effective anti-tuberculosis activity. Ilamycin C is a novel compound isolated from the deep South China Sea- derived Streptomyces atratus SCSIO ZH16 and exhibited a strong cytotoxic activity against several cancers including breast cancer cell line MCF7. However, the cytotoxic activity of Ilamycin C to TNBC cells and a detailed antitumor mechanism have not been reported. Methods: CCK-8 assays were used to examine cell viability and cytotoxic activity of Ilamycin C to TNBC, non-TNBC MCF7, and nonmalignant MCF10A cells. EdU assays and flow cytometry were performed to assess cell proliferation and cell apoptosis. Transwell migration and Matrigel invasion assays were utilized to assess the migratory and invading capacity of TNBC cells following the treatment of Ilamycin C. The expressions of proteins were detected by western blot. Results: In this study, we found that Ilamycin C has more preferential cytotoxicity in TNBC cells than non-TNBC MCF7 and nonmalignant MCF10A cells.
    [Show full text]
  • Thromboxane A2 Receptor Antagonist SQ29548 Attenuates SH‑SY5Y Neuroblastoma Cell Impairments Induced by Oxidative Stress
    INTERNATIONAL JOURNAL OF MOleCular meDICine 42: 479-488, 2018 Thromboxane A2 receptor antagonist SQ29548 attenuates SH‑SY5Y neuroblastoma cell impairments induced by oxidative stress GAOYU CAI1*, AIJUAN YAN2*, NINGZHEN FU3 and YI FU1 1Department of Neurology, Rui Jin Hospital, Shanghai Jiao Tong University, Shanghai 200025; 2Department of Neurology, Xin Hua Hospital, Shanghai Jiao Tong University, Shanghai 200082; 3Department of Pancreatic Surgery, Rui Jin College of Clinical Medicine, Rui Jin Hospital, Shanghai Jiao Tong University, Shanghai 200025, P.R. China Received September 28, 2017; Accepted March 21, 2018 DOI: 10.3892/ijmm.2018.3589 Abstract. Thromboxane A2 receptor (TXA2R) serves a vital SQ29548, an antagonist of TXA2R, improved the antioxidant role in numerous neurological disorders. Our previous study capacities of SH-SY5Y cells and reduced the cell apoptosis indicated that SQ29548, an antagonist of TXA2R, attenuated through the inhibition of MAPK pathways. the induced neuron damage in cerebral infarction animals; however, the underlying mechanism remains unknown. Introduction Certain studies revealed a new role of TXA2R in the regula- tion of oxidative stress, which is one of the basic pathological Thromboxane A2 receptor (TXA2R), a member of the G processes in neurological disorders. Thus, the present study protein-coupled receptor family (1), is broadly distributed attempted to examine whether the inhibition of TXA2R with in platelets (2), as well as epithelial (3), smooth muscle (4), SQ29548 helped to protect the nerve cells against oxidative glial and nerve cells in the brain (5). TXA2R is regarded as a stress. SQ29548 was utilized as a TXA2R antagonist, and traditional coagulation and inflammation‑associated receptor, relevant assays were performed to detect the cell viability, which is also closely associated with neurological disorders.
    [Show full text]
  • Natural Products As Alternative Choices for P-Glycoprotein (P-Gp) Inhibition
    Review Natural Products as Alternative Choices for P-Glycoprotein (P-gp) Inhibition Saikat Dewanjee 1,*, Tarun K. Dua 1, Niloy Bhattacharjee 1, Anup Das 2, Moumita Gangopadhyay 3, Ritu Khanra 1, Swarnalata Joardar 1, Muhammad Riaz 4, Vincenzo De Feo 5,* and Muhammad Zia-Ul-Haq 6,* 1 Advanced Pharmacognosy Research Laboratory, Department of Pharmaceutical Technology, Jadavpur University, Raja S C Mullick Road, Kolkata 700032, India; [email protected] (T.K.D.); [email protected] (N.B.); [email protected] (R.K.); [email protected] (S.J.) 2 Department of Pharmaceutical Technology, ADAMAS University, Barasat, Kolkata 700126, India; [email protected] 3 Department of Bioechnology, ADAMAS University, Barasat, Kolkata 700126, India; [email protected] 4 Department of Pharmacy, Shaheed Benazir Bhutto University, Sheringal 18050, Pakistan; [email protected] 5 Department of Pharmacy, Salerno University, Fisciano 84084, Salerno, Italy 6 Environment Science Department, Lahore College for Women University, Jail Road, Lahore 54600, Pakistan * Correspondence: [email protected] (S.D.); [email protected] (V.D.F.); [email protected] (M.Z.-U.-H.) Academic Editor: Maria Emília de Sousa Received: 11 April 2017; Accepted: 15 May 2017; Published: 25 May 2017 Abstract: Multidrug resistance (MDR) is regarded as one of the bottlenecks of successful clinical treatment for numerous chemotherapeutic agents. Multiple key regulators are alleged to be responsible for MDR and making the treatment regimens ineffective. In this review, we discuss MDR in relation to P-glycoprotein (P-gp) and its down-regulation by natural bioactive molecules. P-gp, a unique ATP-dependent membrane transport protein, is one of those key regulators which are present in the lining of the colon, endothelial cells of the blood brain barrier (BBB), bile duct, adrenal gland, kidney tubules, small intestine, pancreatic ducts and in many other tissues like heart, lungs, spleen, skeletal muscles, etc.
    [Show full text]
  • Supplemetal Materials and Methods Materials Arctiin and Arctigenin
    Supplemetal materials and Methods Materials Arctiin and arctigenin were separated and purified by our laboratory and the final product shown an over 98% purity by HPLC detection. Trandrine tablets were provided by Zhejiang Jinhua Conba Bio-Pharm. CO., LTD. China. Silica (SiO2 purity >99%, particle size 0.5-10 μm (approx. 80% between 1-5 μm) was purchased from Sigma, St., Louse, MO, USA. Penicillin G was suppied by North China Pharmaceutical Co., Ltd. 2-ketoglutaric acid, pyruvic acid, succinic acid, disodium fumarate, malic acid, stearic acid, 3-hydroxytyramine hydrochloride and mixed amino acid standards were purchased from Sigma, USA. Betaine, allantoin, inosine, taurine, creatinine, L-carnitine, creatine, urea and citric acid were recruited from Aladdin, USA. Sodium lactate, doxifluridine, D-(+)-pantothenic acid calcium salt and 6-hydroxypurine were purchased from the National Institutes for Food and Drug Control, China. TNF-α, IL- 1β, NF-κB and TGF-β ELISA kit (FANKEL BIO, Shanghai, China), Hydroxyproline (HYP), ceruloplasmin and lysozyme assay kits (Jiancheng Bioengineering Institute, Nanjing, China). The mitochondrial membrane potential assay kit (Beyotime Biotechnology, Shanghai, China.), reactive oxygen species assay kit (Jiancheng Bioengineering Institute, Nanjing, China.), SDS-PAGE Sample Loading Buffer (Beyotime, Shanghai, China), BCA Protein Assay Kit (Beyotime, Shanghai, China). Antibodies against the following proteins were used: α-SMA, NF-κB, TLR-4, Myd88, NLRP3, ASC, cleaved Caspase-1 (Wanleibio, Shenyang, China), β-actin (Absci, USA), HRP-conjugated goat antirabbit IgG (Wanleibio, Shenyang, China), BeyoECL Plus (Beyotime, Shanghai, China). Dose selection The daily dose interval of Fructus Arctii is 6 - 12 g according to Chinese Pharmacopoeia, in which the arctigenin account for 5% of Fructus Arctii.
    [Show full text]
  • Comprehensive Genetic Testing for Primary Immunodeficiency
     Woon and Ameratunga Allergy Asthma Clin Immunol (2016) 12:65 Allergy, Asthma & Clinical Immunology DOI 10.1186/s13223-016-0169-2 RESEARCH Open Access Comprehensive genetic testing for primary immunodeficiency disorders in a tertiary hospital: 10‑year experience in Auckland, New Zealand See‑Tarn Woon and Rohan Ameratunga* Abstract Background and purpose: New Zealand is a developed geographically isolated country in the South Pacific with a population of 4.4 million. Genetic diagnosis is the standard of care for most patients with primary immunodeficiency disorders (PIDs). Methods: Since 2005, we have offered a comprehensive genetic testing service for PIDs and other immune-related disorders with a published sequence. Here we present results for this program, over the first decade, between 2005 and 2014. Results: We undertook testing in 228 index cases and 32 carriers during this time. The three most common test requests were for X-linked lymphoproliferative (XLP), tumour necrosis factor receptor associated periodic syndrome (TRAPS) and haemophagocytic lymphohistiocytosis (HLH). Of the 32 suspected XLP cases, positive diagnoses were established in only 2 patients. In contrast, genetic defects in 8 of 11 patients with suspected X-linked agammaglobu‑ linemia (XLA) were confirmed. Most XLA patients were initially identified from absence of B cells. Overall, positive diagnoses were made in about 23% of all tests requested. The diagnostic rate was lowest for several conditions with locus heterogeneity. Conclusions: Thorough clinical characterisation of patients can assist in prioritising which genes should be tested. The clinician-driven customised comprehensive genetic service has worked effectively for New Zealand. Next genera‑ tion sequencing will play an increasing role in disorders with locus heterogeneity.
    [Show full text]
  • Anti-Toxoplasma Gondii Effects of a Novel Spider Peptide XYP1 in Vitro and in Vivo
    biomedicines Article Anti-Toxoplasma gondii Effects of a Novel Spider Peptide XYP1 In Vitro and In Vivo Yuan Liu 1,†, Yaqin Tang 1,†, Xing Tang 2,†, Mengqi Wu 1, Shengjie Hou 1, Xiaohua Liu 1, Jing Li 1, Meichun Deng 3, Shuaiqin Huang 1 and Liping Jiang 1,4,* 1 Department of Parasitology, Xiangya School of Medicine, Central South University, Changsha 410013, China; [email protected] (Y.L.); [email protected] (Y.T.); [email protected] (M.W.); [email protected] (S.H.); [email protected] (X.L.); [email protected] (J.L.); [email protected] (S.H.) 2 Hunan Key Laboratory for Conservation and Utilization of Biological Resources in the Nanyue Mountainous Region, Hengyang Normal University, Hengyang 421008, China; [email protected] 3 Department of Biochemistry and Molecular Biology, School of Life Sciences, Central South University, Changsha 410013, China; [email protected] 4 China-Africa Research Center of Infectious Diseases, Xiangya School of Medicine, Central South University, Changsha 410013, China * Correspondence: [email protected]; Tel.: +86-731-82650556 † These authors have contributed equally to this work. Abstract: Toxoplasmosis, caused by an obligate intracellular parasite Toxoplasma gondii, is one of the most prevalent zoonoses worldwide. Treatments for this disease by traditional drugs have shown numerous side effects, thus effective alternative anti-Toxoplasma strategies or drugs are urgently needed. In this study, a novel spider peptide, XYP1, was identified from the cDNA library of the Citation: Liu, Y.; Tang, Y.; Tang, X.; venom gland of the spider Lycosa coelestis. Our results showed that XYP1 has potent anti-Toxoplasma Wu, M.; Hou, S.; Liu, X.; Li, J.; Deng, activity in vitro and in vivo.
    [Show full text]
  • Are Complement Deficiencies Really Rare?
    G Model MIMM-4432; No. of Pages 8 ARTICLE IN PRESS Molecular Immunology xxx (2014) xxx–xxx Contents lists available at ScienceDirect Molecular Immunology j ournal homepage: www.elsevier.com/locate/molimm Review Are complement deficiencies really rare? Overview on prevalence, ଝ clinical importance and modern diagnostic approach a,∗ b Anete Sevciovic Grumach , Michael Kirschfink a Faculty of Medicine ABC, Santo Andre, SP, Brazil b Institute of Immunology, University of Heidelberg, Heidelberg, Germany a r a t b i c s t l e i n f o r a c t Article history: Complement deficiencies comprise between 1 and 10% of all primary immunodeficiencies (PIDs) accord- Received 29 May 2014 ing to national and supranational registries. They are still considered rare and even of less clinical Received in revised form 18 June 2014 importance. This not only reflects (as in all PIDs) a great lack of awareness among clinicians and gen- Accepted 23 June 2014 eral practitioners but is also due to the fact that only few centers worldwide provide a comprehensive Available online xxx laboratory complement analysis. To enable early identification, our aim is to present warning signs for complement deficiencies and recommendations for diagnostic approach. The genetic deficiency of any Keywords: early component of the classical pathway (C1q, C1r/s, C2, C4) is often associated with autoimmune dis- Complement deficiencies eases whereas individuals, deficient of properdin or of the terminal pathway components (C5 to C9), are Warning signs Prevalence highly susceptible to meningococcal disease. Deficiency of C1 Inhibitor (hereditary angioedema, HAE) Meningitis results in episodic angioedema, which in a considerable number of patients with identical symptoms Infections also occurs in factor XII mutations.
    [Show full text]
  • Herbal Principles in Cosmetics Properties and Mechanisms of Action Traditional Herbal Medicines for Modern Times
    Traditional Herbal Medicines for Modern Times Herbal Principles in Cosmetics Properties and Mechanisms of Action Traditional Herbal Medicines for Modern Times Each volume in this series provides academia, health sciences, and the herbal medicines industry with in-depth coverage of the herbal remedies for infectious diseases, certain medical conditions, or the plant medicines of a particular country. Series Editor: Dr. Roland Hardman Volume 1 Shengmai San, edited by Kam-Ming Ko Volume 2 Rasayana: Ayurvedic Herbs for Rejuvenation and Longevity, by H.S. Puri Volume 3 Sho-Saiko-To: (Xiao-Chai-Hu-Tang) Scientific Evaluation and Clinical Applications, by Yukio Ogihara and Masaki Aburada Volume 4 Traditional Medicinal Plants and Malaria, edited by Merlin Willcox, Gerard Bodeker, and Philippe Rasoanaivo Volume 5 Juzen-taiho-to (Shi-Quan-Da-Bu-Tang): Scientific Evaluation and Clinical Applications, edited by Haruki Yamada and Ikuo Saiki Volume 6 Traditional Medicines for Modern Times: Antidiabetic Plants, edited by Amala Soumyanath Volume 7 Bupleurum Species: Scientific Evaluation and Clinical Applications, edited by Sheng-Li Pan Traditional Herbal Medicines for Modern Times Herbal Principles in Cosmetics Properties and Mechanisms of Action Bruno Burlando, Luisella Verotta, Laura Cornara, and Elisa Bottini-Massa Cover art design by Carlo Del Vecchio. CRC Press Taylor & Francis Group 6000 Broken Sound Parkway NW, Suite 300 Boca Raton, FL 33487-2742 © 2010 by Taylor and Francis Group, LLC CRC Press is an imprint of Taylor & Francis Group, an Informa business No claim to original U.S. Government works Printed in the United States of America on acid-free paper 10 9 8 7 6 5 4 3 2 1 International Standard Book Number-13: 978-1-4398-1214-3 (Ebook-PDF) This book contains information obtained from authentic and highly regarded sources.
    [Show full text]
  • Multiple Myeloma Inhibitory Activity of Plant Natural Products
    cancers Review Multiple Myeloma Inhibitory Activity of Plant Natural Products Karin Jöhrer 1 and Serhat Sezai Ҫiҫek 2,* 1 Tyrolean Cancer Research Institute, Innrain 66, 6020 Innsbruck, Austria; karin.joehrer@tkfi.at 2 Department of Pharmaceutical Biology, Kiel University, Gutenbergstraße 76, 24118 Kiel, Germany * Correspondence: [email protected] Simple Summary: Multiple myeloma is the second most common hematological cancer and is still incurable. Although enhanced understanding of the disease background and the development of novel therapeutics during the last decade resulted in a significant increase of overall survival time, almost all patients relapse and finally succumb to their disease. Therefore, novel medications are urgently needed. Nature-derived compounds still account for the majority of new therapeutics and especially for the treatment of cancer often serve as lead compounds in drug development. The present review summarizes the data on plant natural products with in vitro and in vivo activity against multiple myeloma until the end of 2020, focusing on their structure–activity relationship as well as the investigated pathways and involved molecules. Abstract: A literature search on plant natural products with antimyeloma activity until the end of 2020 resulted in 92 compounds with effects on at least one human myeloma cell line. Compounds were divided in different compound classes and both their structure–activity-relationships as well as eventual correlations with the pathways described for Multiple Myeloma were discussed. Each of the major compound classes in this review (alkaloids, phenolics, terpenes) revealed interesting candidates, such as dioncophyllines, a group of naphtylisoquinoline alkaloids, which showed pronounced Citation: Jöhrer, K.; Ҫiҫek, S.S.
    [Show full text]
  • Hereditary Angioedema: a Broad Review for Clinicians
    REVIEW ARTICLE Hereditary Angioedema A Broad Review for Clinicians Ugochukwu C. Nzeako, MD, MPH; Evangelo Frigas, MD; William J. Tremaine, MD ereditary angioedema (HAE) is an autosomal dominant disease that afflicts 1 in 10000 to 1 in 150000 persons; HAE has been reported in all races, and no sex predomi- nance has been found. It manifests as recurrent attacks of intense, massive, localized edema without concomitant pruritus, often resulting from one of several known trig- Hgers. However, attacks can occur in the absence of any identifiable initiating event. Historically, 2 types of HAE have been described. However, a variant, possibly X-linked, inherited angioedema has recently been described, and tentatively it has been named “type 3” HAE. Signs and symptoms are identical in all types of HAE. Skin and visceral organs may be involved by the typically massive local edema. The most commonly involved viscera are the respiratory and gastrointestinal sys- tems. Involvement of the upper airways can result in severe life-threatening symptoms, including the risk of asphyxiation, unless appropriate interventions are taken. Quantitative and functional analyses of C1 esterase inhibitor and complement components C4 and C1q should be performed when HAE is suspected. Acute exacerbations of the disease should be treated with intravenous purified C1 esterase inhibitor concentrate, where available. Intravenous administration of fresh frozen plasma is also useful in acute HAE; however, it occasionally exacerbates symptoms. Corti- costeroids, antihistamines, and epinephrine can be useful adjuncts but typically are not effica- cious in aborting acute attacks. Prophylactic management involves long-term use of attenuated androgens or antifibrinolytic agents.
    [Show full text]